Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

ALRAG Invest Germany has issued bonds
Real Estate

ALRAG Invest Germany has issued bonds

ALRAG Invest Germany GmbH & Co. KG has completed a fundraising to develop its portfolio.

Learn more
Nutricare has raised US$3.1 million via an entitlement offer
Consumer & Retail | Healthcare

Nutricare has raised US$3.1 million via an entitlement offer

Nutricare Pty Ltd has raised funds to support its growth strategy.

Learn more
Ideagen has completed a US$105 million debt refinancing
TMT

Ideagen has completed a US$105 million debt refinancing

Ideagen Plc. has raised funds to support its next phase of growth.

Learn more